… at assessing the therapeutic profile of aspirin and celecoxib, … -driven cervical cancer, breast
carcinoma and glioma, … these molecules in cancer patients are Phase I/II trials, perhaps …

… acts on the tumor microenvironment to increase the production of … The COX-2 inhibitor
celecoxib enhanced the efficacy of … cancers because it has a potential as a disease biomarker and …

… certain cancers such as cervical, anogenital, oropharyngeal … Celecoxib, a cyclooxygenase-2
(COX-2) inhibitor, promotes … chronic inflammation in tumor microenvironment will hopefully …

… of an immunosuppressive tumor microenvironment (TME) by … trial, a phase I-II study testing
the COX-2 inhibitor celecoxib … to secrete cyclooxygenase 2 (COX-2) and induce cancer stem …

… in EPCs are a potential biomarker of sorafenib efficacy 120 . … a selective cyclooxygenase-2
(COX2) inhibitor (celecoxib) … in phase I/II clinical testing in patients with breast cancer 165 . …

… Cyclooxygenase-2 inhibitor studies in animal models have thrown light on its role in … %,
respectively, in cervical cancer patients receiving chemo-radiotherapy treated with celecoxib [20] …

… of the microbiome and the tumor microenvironment [9]. … skin cancer, melanoma in situ,
Stage I cervical cancer, or … III colon cancer patients to a 3 year intervention of celecoxib or …

… evaluation of durvalumab is taking place in the phase I/II … following BCG treatment, and
cyclooxygenase-2 (COX2) has … clinical trials involving systemic blockade of COX2 (oral celecoxib)…

… ), are able to interfere with tumor microenvironment by reducing cell … of the STAT3 pathway
in cervical cancer. Together, the … FAP patients that used a specific COX-2 inhibitor, celecoxib, …

… Carcinogenic stimuli of the tumor microenvironment promote … Cyclo-Oxigenase 2 inhibitor
celecoxib has been evaluated … solid tumors refractory to standard therapy (cohort I/II), …